Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Oxana Beskrovnaya Sells 2,339 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Oxana Beskrovnaya sold 2,339 shares of the business’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total value of $80,812.45. Following the completion of the sale, the insider now owns 140,375 shares in the company, valued at $4,849,956.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Dyne Therapeutics Stock Up 6.0 %

DYN stock traded up $2.07 during trading on Thursday, hitting $36.41. The company had a trading volume of 2,431,913 shares, compared to its average volume of 1,597,111. Dyne Therapeutics, Inc. has a 52-week low of $6.40 and a 52-week high of $47.45. The company has a 50 day simple moving average of $41.28 and a 200-day simple moving average of $33.47. The firm has a market capitalization of $3.18 billion, a P/E ratio of -9.31 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Monday, August 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. Sell-side analysts forecast that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of DYN. Nisa Investment Advisors LLC grew its position in shares of Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after buying an additional 669 shares in the last quarter. Amalgamated Bank lifted its stake in Dyne Therapeutics by 39.9% in the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after acquiring an additional 796 shares during the period. Ameritas Investment Partners Inc. grew its holdings in Dyne Therapeutics by 28.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock worth $167,000 after acquiring an additional 1,291 shares in the last quarter. Public Employees Retirement Association of Colorado purchased a new position in Dyne Therapeutics during the 2nd quarter valued at about $203,000. Finally, Farallon Capital Management LLC bought a new stake in shares of Dyne Therapeutics in the 2nd quarter valued at about $212,000. 96.68% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, September 4th. Morgan Stanley upped their price target on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Guggenheim lifted their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, August 15th. Piper Sandler upped their target price on shares of Dyne Therapeutics from $43.00 to $53.00 and gave the company an “overweight” rating in a research report on Tuesday, August 13th. Finally, JPMorgan Chase & Co. increased their price target on shares of Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a report on Tuesday, July 9th. One equities research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $51.40.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.